Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07424547 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
A Phase 1 study of Breast Cancer and Cancer, sponsored by Conjupro Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 386
- Enrollment target
- 5
- Study locations
NCT07424547: Recruiting Phase 1 study of Breast Cancer and Cancer, sponsored by Conjupro Biotherapeutics.
NCT07424547 is a Phase 1 study of Breast Cancer and Cancer that is actively recruiting participants, run by Conjupro Biotherapeutics. The registered enrollment target is 386 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07424547, a Phase 1 study of Breast Cancer and Cancer, is actively recruiting participants, sponsored by Conjupro Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 386 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it. In addition, the study will look for early signs that SYS6043 may help slow or shrink tumors and explore whether the amount of a tumor protein called B7-H3 is related to how well the treatment works. Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive SYS6043 by intravenous infusion once every 3 weeks (Q3W), with 21 days as one treatment cycle until the study doctor determines that study treatment should be stopped based on how well a participant is doing on treatment. * Have safety follow-up (SFU), and long-term follow-up. * Be followed until progression.
Primary Outcome
Assessment of the MTD and/or RP2D (recommended Phase II dose).
Conditions Studied
Interventions
- DRUG SYS6043
Study Locations (5)
Florida
- BRCR Global - Plantation
- Florida Clinical Trials Group - Plantation
Texas
- NEXT Oncology Austin - Austin
- NEXT Oncology San Antonio - San Antonio
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2026-03-03 |
| Est. Completion | 2030-04 |
| Phase | Phase 1 |
What NCT07424547 shows while recruiting
NCT07424547 is an interventional study that assigns participants to a tested intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower).
The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which SYS6043 is the first listed.
NCT07424547 lists 5 locations in 3 states (Florida, Texas, Virginia).
Frequently Asked Questions
What is clinical trial NCT07424547 about?
NCT07424547 is a clinical study titled "Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors". The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause...
What is the current status of trial NCT07424547?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 386 participants. The study started on 2026-03-03. Estimated completion is 2030-04.
What conditions does trial NCT07424547 study?
This clinical trial studies the following conditions: Breast Cancer, Cancer, Ovarian Cancer, Small-cell Lung Cancer, Solid Tumor Cancer.
What interventions are being tested in trial NCT07424547?
The interventions under investigation include: SYS6043 (DRUG).
Who is sponsoring clinical trial NCT07424547?
This trial is sponsored by Conjupro Biotherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07424547 being conducted?
This trial has 5 study locations across Florida, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07424547's enrollment target sits among peer trials
386 247th of 1224 higher than 977 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645107 · 386 participants · Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- NCT06686121 · 386 participants · Phase 3
Improving Mobility After Revascularization in Peripheral Artery Disease
- NCT03761108 · 387 participants · Phase 1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- NCT05572632 · 387 participants · NA
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI